What Happened?
New Haven, AB-based Trevi Therapeutics Appointed Lisa Delfini as Chief Financial Officer
About the Company
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
About the Person
Lisa Delfini is Chief Financial Officer at Trevi Therapeutics. Previously, Lisa held various senior HR leadership roles in the industry.
Info Source
News
Short Profile